search
Back to results

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Primary Purpose

Hepatitis B

Status
Completed
Phase
Phase 1
Locations
Indonesia
Study Type
Interventional
Intervention
Recombinant Hepatitis B (Bio Farma) Vaccine
Recombinant Hepatitis B (Bio Farma) Vaccine®
Sponsored by
PT Bio Farma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hepatitis B focused on measuring vaccine, hepatitis b, infection, virus

Eligibility Criteria

10 Years - 40 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Adult

  1. Healthy individu as determined by clinical judgment, including a medical history, physical exam, rontgen thorax and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator.
  2. Subjects have been informed properly regarding the study and signed the informed consent form
  3. Subjects will commit to comply with the instructions of the investigator and the schedule of the trial

Children:

  1. Healthy individu as determined by clinical judgment, including a medical history, physical exam and rontgen thorax which confirms the absence of a current or past disease state considered significant by the investigator.
  2. Subjects/parents/guardian(s) have been informed properly regarding the study and signed the informed consent form and
  3. Subject/parents/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

  1. Subject concomitantly enrolled or scheduled to be enrolled in another trial
  2. Any direct relatives relationship with the study team.
  3. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.
  4. Known history of allergy to any component of the vaccines (based on anamnesis)
  5. Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)
  6. History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
  7. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or corticosteroid therapy and other immunosuppresant).
  8. Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
  9. Pregnancy or planning a pregnancy within the next 3 months & lactation. (for Adults)
  10. Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.
  11. HbsAg positive
  12. Subjects with known history of Hepatitis B infection.
  13. Subjects who have received Hepatitis B vaccination which proven by vaccination records.
  14. Subject planning to move from the study area before the end of study period.

Sites / Locations

  • Hasan Sadikin Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Recombinant Hepatitis B (Bio Farma) Vaccine

Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®

Arm Description

Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.

Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.

Outcomes

Primary Outcome Measures

Number of subjects with Immediate reaction
Number of subjects with at least one immediate reaction (local reaction or systemic event) within 30 minutes after one dose or three doses of Hepatits B vaccination
percentage of subjects with Immediate reaction
Percentage of subjects with at least one immediate reaction (local reaction or systemic event) within 30 minutes after one dose or three doses of Hepatits B vaccination

Secondary Outcome Measures

Number of subjects with Adverse Events from 1 day to 28 days after vaccination
Number of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after each dose vaccination
Percentage of subjects with Adverse Events from 1 day to 28 days after vaccination
Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after each dose vaccination
Number of subjects with Serious Adverse Events from 1 day to 28 days after vaccination
Number of subjects with serious adverse event from inclusion until 28 day after each dose vaccination.
Percentage of subjects with serious Adverse Events from 1 day to 28 days after vaccination
Percentage of subjects with serious adverse event from inclusion until 28 day after each dose vaccination.
Number of Lab Deviation for adults subjects in 7 days of immunization
Number of deviation from routine biochemical (SGOT, SGPT, Ureum, Creatinine) and Hematological (Hb, Hct, Dif, Leucocyte count, Total Leucocyte, total Eryhrocyte, total Thrombocyte) laboratory evaluation that probably related to the vaccination (adults subject).
Safety Comparison between each intervention group
incidence of any adverse event, compared between two intervention arms
Protectivity of Hepatitis B vaccine (number of subject with protective anti HbsAg)
Number of subjects with anti-HbsAg more than 10mIU/ml, 28 days after 1 dose or three doses of vaccination.
Protectivity of Hepatitis B vaccine (4 times increasing antibody)
- Number and percentage of subjects with more than 4 folds increasing antibody
Protectivity of Hepatitis B vaccine (Geometic Mean Titers)
- Geometric Mean Titers (GMT) following immunization
Anti-HBs description between groups
Number of subjects with protective Anti-HBs value, compared between intervention groups after vaccination.

Full Information

First Posted
November 27, 2019
Last Updated
July 29, 2022
Sponsor
PT Bio Farma
search

1. Study Identification

Unique Protocol Identification Number
NCT04188223
Brief Title
Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children
Official Title
Safety and Preliminary of Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children (Phase I)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
December 3, 2019 (Actual)
Primary Completion Date
July 16, 2020 (Actual)
Study Completion Date
July 16, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PT Bio Farma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is an experimental, randomized, double blind, prospective intervention study Approximately 100 subjects will be enrolled in this trial, divided into 2 arms, as follow: For adult (18-40 years old)
Detailed Description
Each study age group/arm will be divided into two groups of treatment. One group will receive investigational product and one other group will receive active comparator. This Study is sequential age de-escalation. To be conducted in heathy adults (18-40 years old) and followed by children (10-17 years old) ). Before the study started, the subjects will be assessed for anti HBs Antibody. For subjects with anti-HBs not protective (< 10mIU/mL) before immunization, additional 2 doses will be required with 1 month interval.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B
Keywords
vaccine, hepatitis b, infection, virus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
This Study is sequential age de-escalation. To be conducted in heathy adults (18-40 years old) and followed by children (10-17 years old) )
Masking
ParticipantInvestigator
Masking Description
Double blind.
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Recombinant Hepatitis B (Bio Farma) Vaccine
Arm Type
Experimental
Arm Description
Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
Arm Title
Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®
Arm Type
Active Comparator
Arm Description
Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
Intervention Type
Biological
Intervention Name(s)
Recombinant Hepatitis B (Bio Farma) Vaccine
Intervention Description
Recombinant Hepatitis B vaccine produced by Bio Farma
Intervention Type
Biological
Intervention Name(s)
Recombinant Hepatitis B (Bio Farma) Vaccine®
Intervention Description
Registered Recombinant Hepatitis B vaccine produced by Bio Farma
Primary Outcome Measure Information:
Title
Number of subjects with Immediate reaction
Description
Number of subjects with at least one immediate reaction (local reaction or systemic event) within 30 minutes after one dose or three doses of Hepatits B vaccination
Time Frame
3 months
Title
percentage of subjects with Immediate reaction
Description
Percentage of subjects with at least one immediate reaction (local reaction or systemic event) within 30 minutes after one dose or three doses of Hepatits B vaccination
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Number of subjects with Adverse Events from 1 day to 28 days after vaccination
Description
Number of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after each dose vaccination
Time Frame
3 months
Title
Percentage of subjects with Adverse Events from 1 day to 28 days after vaccination
Description
Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after each dose vaccination
Time Frame
3 months
Title
Number of subjects with Serious Adverse Events from 1 day to 28 days after vaccination
Description
Number of subjects with serious adverse event from inclusion until 28 day after each dose vaccination.
Time Frame
3 Months
Title
Percentage of subjects with serious Adverse Events from 1 day to 28 days after vaccination
Description
Percentage of subjects with serious adverse event from inclusion until 28 day after each dose vaccination.
Time Frame
3 Months
Title
Number of Lab Deviation for adults subjects in 7 days of immunization
Description
Number of deviation from routine biochemical (SGOT, SGPT, Ureum, Creatinine) and Hematological (Hb, Hct, Dif, Leucocyte count, Total Leucocyte, total Eryhrocyte, total Thrombocyte) laboratory evaluation that probably related to the vaccination (adults subject).
Time Frame
7 Days After 1st Vaccination
Title
Safety Comparison between each intervention group
Description
incidence of any adverse event, compared between two intervention arms
Time Frame
3 months
Title
Protectivity of Hepatitis B vaccine (number of subject with protective anti HbsAg)
Description
Number of subjects with anti-HbsAg more than 10mIU/ml, 28 days after 1 dose or three doses of vaccination.
Time Frame
3 months
Title
Protectivity of Hepatitis B vaccine (4 times increasing antibody)
Description
- Number and percentage of subjects with more than 4 folds increasing antibody
Time Frame
3 months
Title
Protectivity of Hepatitis B vaccine (Geometic Mean Titers)
Description
- Geometric Mean Titers (GMT) following immunization
Time Frame
3 months
Title
Anti-HBs description between groups
Description
Number of subjects with protective Anti-HBs value, compared between intervention groups after vaccination.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult Healthy individu as determined by clinical judgment, including a medical history, physical exam, rontgen thorax and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator. Subjects have been informed properly regarding the study and signed the informed consent form Subjects will commit to comply with the instructions of the investigator and the schedule of the trial Children: Healthy individu as determined by clinical judgment, including a medical history, physical exam and rontgen thorax which confirms the absence of a current or past disease state considered significant by the investigator. Subjects/parents/guardian(s) have been informed properly regarding the study and signed the informed consent form and Subject/parents/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: Subject concomitantly enrolled or scheduled to be enrolled in another trial Any direct relatives relationship with the study team. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment. Known history of allergy to any component of the vaccines (based on anamnesis) Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy) History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or corticosteroid therapy and other immunosuppresant). Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. Pregnancy or planning a pregnancy within the next 3 months & lactation. (for Adults) Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization. HbsAg positive Subjects with known history of Hepatitis B infection. Subjects who have received Hepatitis B vaccination which proven by vaccination records. Subject planning to move from the study area before the end of study period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kusnandi Rusmil, Professor
Organizational Affiliation
Padjadjaran University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hasan Sadikin Hospital
City
Bandung
State/Province
West Java
ZIP/Postal Code
40161
Country
Indonesia

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

We'll reach out to this number within 24 hrs